Company Overview and News

 
Yara: A Growing Fertilizer Company With Historically Strong Returns

2018-10-15 seekingalpha
The fertilizer industry is slowly recovering from the problems that it had a few years ago although it is not as strong as it once was.
YRAIF TTQQY YARIY 500770 TATACHEM

 
Use pullback rallies to initiate fresh shorts; 3 stocks which can return up to 15%

2018-10-05 moneycontrol
Rising crude oil prices, fall in the Indian rupee against the US dollar, rising interest rates and macro concerns put tremendous pressure on Indian bourses. The broader indices have corrected by more than 3 percent in the last three sessions.
TTQQY 500770 TATACHEM

3
A 'Steady Eddie' Niche Leader With An 8% Yield And A Q2 Windfall

2018-09-29 seekingalpha - 2
The company received a one-time $26M litigation settlement in Q2, which increased EBITDA and DCF dramatically.
CINR NRP TTQQY 500770 TATACHEM

 
Tata Chemicals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TTQQY 500770 TATACHEM

 
Tata Chemicals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TTQQY 500770 TATACHEM

 
Use rallies in Nifty to reduce naked leverage positions; 3 stocks which could give 5-8% return

2018-09-11 moneycontrol
The market ended lower after six consecutive weeks of the rise and lost nearly a percent on Monday. Participants were in the profit-taking mood from the beginning, citing feeble global cues and not so encouraging domestic data.
TTQQY 500477 AKLS AKLD 500770 TATACHEM ASHOKLEY

 
D-Street Buzz: FMCG stocks fall dragged by Jubilant Food, HUL; IT stocks rally with Infosys up 3%, hits new 52-week high

2018-09-04 moneycontrol
The market sentiment is negative this Tuesday morning after the rupee slipped to yet another record low against the US dollar. The benchmark indices including the Nifty50 shed 42 points at 11,540 while the Sensex is trading lower by 86 points at 38,226.
500325 DABUR BRIGADE BRTQY TCHQY TTQQY 532755 DBRQY 532710 TATACHEM SYNDIBANK 500096 532483 500696 BRITANNIA 500770 502355 RLNIY SBAZ RELCAPITAL YYBKY 530005 ALBERTDA CNRYY TECHM 532276 TCS CANBK ANDHRABANK BALKRISIND 500825 RELIANCE 532418 HINDUNILVR 533155 TATACOMM NAUKRI TTNQY JUBLFOOD 532777 532540 RIGD JBLWY SADBHAV INDIACEM 500111 YESBANK UBNC 517354 HVLQY 532929 532648 524075 HAVELLS 501455 GREAVESCOT 500483

 
Tata Chemicals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TTQQY 500770 TATACHEM

 
Market Live: Sensex, Nifty under pressure amid rupee weakness, higher crude oil prices

2018-08-30 moneycontrol
Following the 2013 episode, which was far more disruptive from a macroeconomic stability perspective, Indian policymakers initiated a number of steps to safeguard the economy.
YESBANK 500325 KMBKY IBN RELIANCE TTQQY 532648 YYBKY TATACHEM 532179 ICICIBANK 532121 CRPKY 532174 RIGD KOTAKBANK 501455 CORPBANK 500247 GREAVESCOT DENABANK 500770 RLNIY

3
Tata Chemicals dips 2% after ICICI Prudential reduces its stake by 2% in Co

2018-08-30 moneycontrol
Shares of Tata Chemicals declined 2.2 percent intraday Thursday after ICICI Prudential Life Insurance has reduced its stake in the company.
BRK.A TTQQY 500770 TATACHEM

 
I-Pru pares stake in Tata Chem

2018-08-29 thehindubusinessline
ICICI Prudential Life Insurance has reduced its stake in Tata Chemicals to 2.97 per cent. After selling a stake on Tuesday, its cumulative change in holding got reduced by more than 2 per cent in Tata Chemicals, the insurance company said in a notice to the bourses. ICICI Prudential was holding 5.02 per cent in the company at the end of June 30, 2017. On Wednesday, the shares of Tata Chemicals closed at ₹758.
TTQQY 500770 TATACHEM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...